China, Nov. 3 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Efficacy of Teprotumumab N01 Injection in Patients with Thyroid Eye Disease Refractory to Radiotherapy'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600135818
Registration Time: 2026/11/02
Type: Interventional study
Primary Sponsor: China National Nuclear Corporation 416 Hospital
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=291452
Published by HT Digital Content Services with permission from Health Daily Digest....